H9FF人类胚胎干细胞（无滋养层）

人胚胎干细胞H9，曾用名WA09。每支细胞可复苏至一个T25，3至4天后会形成30至40个克隆。将H9（SCSP-302）细胞使用mTeSR1（STEM CELL）培养液驯化后得到，培养时无需饲养层。

组织来源 Tissue and Cell Type ：人胚胎内细胞团

形态/Morphology ：球形克隆，贴壁生长

培养基和添加剂/Complete Growth Medium and Culture Conditions：

使用 hES/hiPS无血清培养液套装（SCSP-662）培养、传代、冻存。

备注:

完全培养液： mTeSR1 人ES/iPS细胞无饲养层完全培养试剂盒 （Stem cell, 货号 85850）

传代消化液：温和分离细胞试剂 （Stem cell, 货号 07174）

冻存液：无血清无动物成分细胞冻存液 （Stem cell, 货号 07930）

基质胶：hES 专用基质胶 （BD，货号354277）

气相：空气，95%；二氧化碳，5%。 温度：37摄氏度。

完全冻存液：免程序降温细胞冻存液（低血清）(SD0001)

注意事项：此产品仅供科研使用。

PubMed=2567177; DOI=10.1089/aid.1989.5.253

Mann D.L., O'Brien S.J., Gilbert D.A., Reid Y.A., Popovic M., Read-Connole E., Gallo R.C., Gazdar A.F.

Origin of the HIV-susceptible human CD4+ cell line H9.

AIDS Res. Hum. Retroviruses 5:253-255(1989)

PubMed=2193399; DOI=10.1126/science.2193399

Rubinstein E.

The untold story of HUT78.

Science 248:1499-1507(1990)

PubMed=1460674; DOI=10.1093/jnci/84.24.1922

Chen T.-R.

Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility.

J. Natl. Cancer Inst. 84:1922-1926(1992)

PubMed=8320746; DOI=10.1093/jnci/85.14.1168

Bunn P.A. Jr., Whang-Peng J., Gazdar A.F., Minna J.D., Carney D.N.

Karyotypic derivation of H9 cell line.

J. Natl. Cancer Inst. 85:1168-1169(1993)

PubMed=8127147

Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.

Interferon system defects in malignant T-cells.

Leukemia 8:425-434(1994)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x

Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.

p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.

Eur. J. Haematol. 56:313-318(1996)

PubMed=17170727; DOI=10.1038/sj.leu.2404486

Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M., de Vos J., Macleod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M., Langerak A.W.

Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.

Leukemia 21:230-237(2007)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)